keyword
https://read.qxmd.com/read/38600974/cbx7c%C3%A2-phc2-interaction-facilitates-prc1-assembly-and-modulates-its-phase-separation-properties
#1
JOURNAL ARTICLE
Shanli Guan, Jiajia Tang, Xiaojun Ma, Ruidong Miao, Bo Cheng
CBX7 is a key component of PRC1 complex. Cbx7C is an uncharacterized Cbx7 splicing isoform specifically expressed in mouse embryonic stem cells (mESCs). We demonstrate that CBX7C functions as an epigenetic repressor at the classic PRC1 targets in mESCs, and its preferential interaction to PHC2 facilitates PRC1 assembly. Both Cbx7C and Phc2 are significantly upregulated during cell differentiation, and knockdown of Cbx7C abolishes the differentiation of mESCs to embryoid bodies. Interestingly, CBX7C⋅PHC2 interaction at low levels efficiently undergoes the formation of functional Polycomb bodies with high mobility, whereas the coordination of the two factors at high doses results in the formation of large, low-mobility, chromatin-free aggregates...
April 19, 2024: IScience
https://read.qxmd.com/read/38562687/the-prc2-1-subcomplex-opposes-g1-progression-through-regulation-of-ccnd1-and-ccnd2
#2
Adam D Longhurst, Kyle Wang, Harsha Garadi Suresh, Mythili Ketavarapu, Henry N Ward, Ian R Jones, Vivek Narayan, Frances V Hundley, Arshia Zernab Hassan, Charles Boone, Chad L Myers, Yin Shen, Vijay Ramani, Brenda J Andrews, David P Toczyski
Progression through the G1 phase of the cell cycle is the most highly regulated step in cellular division. We employed a chemogenomics approach to discover novel cellular networks that regulate cell cycle progression. This approach uncovered functional clusters of genes that altered sensitivity of cells to inhibitors of the G1/S transition. Mutation of components of the Polycomb Repressor Complex 2 rescued growth inhibition caused by the CDK4/6 inhibitor palbociclib, but not to inhibitors of S phase or mitosis...
March 19, 2024: bioRxiv
https://read.qxmd.com/read/38543731/discovery-of-a-novel-antiviral-effect-of-the-restriction-factor-spoc1-against-human-cytomegalovirus
#3
JOURNAL ARTICLE
Anna K Kuderna, Anna Reichel, Julia Tillmanns, Maja Class, Myriam Scherer, Thomas Stamminger
The chromatin-remodeler SPOC1 (PHF13) is a transcriptional co-regulator and has been identified as a restriction factor against various viruses, including human cytomegalovirus (HCMV). For HCMV, SPOC1 was shown to block the onset of immediate-early (IE) gene expression under low multiplicities of infection (MOI). Here, we demonstrate that SPOC1-mediated restriction of IE expression is neutralized by increasing viral titers. Interestingly, our study reveals that SPOC1 exerts an additional antiviral function beyond the IE phase of HCMV replication...
February 27, 2024: Viruses
https://read.qxmd.com/read/38457926/c-terminal-binding-protein-ctbp2-is-a-novel-tumor-suppressor-targeting-the-myc-irf4-axis-in-multiple-myeloma
#4
JOURNAL ARTICLE
Coty Hy Cheung, Chi Keung Cheng, Kam Tong Leung, Chi Zhang, Chi Yan Ho, Xi Luo, Angel Yf Kam, Tian Xia, Thomas Sk Wan, Herbert Augustus Pitts, Natalie Pui Ha Chan, Joyce Sin Cheung, Raymond Siu Ming Wong, Xiao-Bing Zhang, Margaret Hl Ng
Multiple myeloma (MM) cells are addicted to MYC and its direct transactivation target IRF4 for proliferation and survival. MYC and IRF4 are still considered "undruggable" as the majority of small molecule inhibitors suffers from low potency, suboptimal pharmacokinetic properties and undesirable off-target effects. Indirect inhibition of MYC/IRF4 emerges as a therapeutic vulnerability in MM. Here, we uncover an unappreciated tumor suppressive role of C-terminal Binding Protein 2 (CTBP2) in MM via strong inhibition of the MYC-IRF4 axis...
March 8, 2024: Blood Advances
https://read.qxmd.com/read/38453932/kdm1a-safeguards-the-topological-boundaries-of-prc2-repressed-genes-and-prevents-aging-related-euchromatinization-in-neurons
#5
JOURNAL ARTICLE
Beatriz Del Blanco, Sergio Niñerola, Ana M Martín-González, Juan Paraíso-Luna, Minji Kim, Rafael Muñoz-Viana, Carina Racovac, Jose V Sanchez-Mut, Yijun Ruan, Ángel Barco
Kdm1a is a histone demethylase linked to intellectual disability with essential roles during gastrulation and the terminal differentiation of specialized cell types, including neurons, that remains highly expressed in the adult brain. To explore Kdm1a's function in adult neurons, we develop inducible and forebrain-restricted Kdm1a knockouts. By applying multi-omic transcriptome, epigenome and chromatin conformation data, combined with super-resolution microscopy, we find that Kdm1a elimination causes the neuronal activation of nonneuronal genes that are silenced by the polycomb repressor complex and interspersed with active genes...
March 7, 2024: Nature Communications
https://read.qxmd.com/read/38349881/cop1-controls-light-dependent-chromatin-remodeling
#6
JOURNAL ARTICLE
Wenli Wang, Junghyun Kim, Teresa S Martinez, Enamul Huq, Sibum Sung
Light is a crucial environmental factor that impacts various aspects of plant development. Phytochromes, as light sensors, regulate myriads of downstream genes to mediate developmental reprogramming in response to changes in environmental conditions. CONSTITUTIVELY PHOTOMORPHOGENIC 1 (COP1) is an E3 ligase for a number of substrates in light signaling, acting as a central repressor of photomorphogenesis. The interplay between phytochrome B (phyB) and COP1 forms an antagonistic regulatory module that triggers extensive gene expression reprogramming when exposed to light...
February 20, 2024: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/38315170/polycomb-repressor-complex-2-suppresses-interferon-responsive-mhc-ii-expression-in-melanoma-cells-and-is-associated-with-anti-pd-1-resistance
#7
JOURNAL ARTICLE
Jamaal L James, Brandie C Taylor, Margaret L Axelrod, Xiaopeng Sun, Lindsey N Guerin, Paula I Gonzalez-Ericsson, Yu Wang, Violeta Sanchez, Catherine C Fahey, Melinda E Sanders, Yaomin Xu, Emily Hodges, Douglas B Johnson, Justin M Balko
BACKGROUND: Despite the remarkable success of immunotherapy in treating melanoma, understanding of the underlying mechanisms of resistance remains limited. Emerging evidence suggests that upregulation of tumor-specific major histocompatibility complex-II (tsMHC-II) serves as a predictive marker for the response to anti-programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) therapy in various cancer types. The genetic and epigenetic pathways modulating tsMHC-II expression remain incompletely characterized...
November 20, 2023: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38288743/polycomb-mediated-histone-modifications-and-gene-regulation
#8
JOURNAL ARTICLE
Shinsuke Ito, Takashi Umehara, Haruhiko Koseki
Polycomb repressive complexes 1 and 2 (PRC1 and PRC2) are transcriptional repressor complexes that play a fundamental role in epigenomic regulation and the cell-fate decision; these complexes are widely conserved in multicellular organisms. PRC1 is an E3 ubiquitin (ub) ligase that generates histone H2A ubiquitinated at lysine (K) 119 (H2AK119ub1), whereas PRC2 is a histone methyltransferase that specifically catalyzes tri-methylation of histone H3K27 (H3K27me3). Genome-wide analyses have confirmed that these two key epigenetic marks highly overlap across the genome and contribute to gene repression...
January 30, 2024: Biochemical Society Transactions
https://read.qxmd.com/read/38155420/the-landscape-of-alterations-affecting-epigenetic-regulators-in-t-cell-acute-lymphoblastic-leukemia-roles-in-leukemogenesis-and-therapeutic-opportunities
#9
REVIEW
Yashna Walia, Charles E de Bock, Yizhou Huang
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy accounting for 10%-15% of pediatric and 20%-25% of adult ALL cases. Epigenetic irregularities in T-ALL include alterations in both DNA methylation and the post-translational modifications on histones which together play a critical role in the initiation and development of T-ALL. Characterizing the oncogenic mutations that result in these epigenetic changes combined with the reversibility of epigenetic modifications represents an opportunity for the development of epigenetic therapies...
December 28, 2023: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/38113003/the-swi-snf-complex-a-frequently-mutated-chromatin-remodeling-complex-in-cancer
#10
JOURNAL ARTICLE
Vinh The Nguyen, Mathewos Tessema, Bernard Ellis Weissman
The switch/sucrose non-fermenting (SWI/SNF) chromatin remodeling complex is a global regulator of gene expression known to maintain nucleosome-depleted regions at active enhancers and promoters. The mammalian SWI/SNF protein subunits are encoded by 29 genes and 11-15 subunits including an ATPase domain of either SMARCA4 (BRG1) or SMARCA2 (BRM) are assembled into a complex. Based on the distinct subunits, SWI/SNF are grouped into 3 major types (subfamilies): the canonical BRG1/BRM-associated factor (BAF/cBAF), polybromo-associated BAF (PBAF), and non-canonical BAF (GBAF/ncBAF)...
2023: Cancer Treatment and Research
https://read.qxmd.com/read/38050190/targeting-polycomb-repressor-complex-2-mediated-bivalent-promoter-epigenetic-silencing-of-secreted-frizzled-related-protein-1-inhibits-cholangiocarcinoma-progression
#11
JOURNAL ARTICLE
Guanhua Wu, Qi Wang, Da Wang, Fei Xiong, Wenzheng Liu, Junsheng Chen, Bing Wang, Wenhua Huang, Xin Wang, Yongjun Chen
BACKGROUND: Cholangiocarcinoma (CCA) refers to a collection of malignancies that are associated with a dismal prognosis. Currently, surgical resection is the only way to cure patients with CCA. Available systemic therapy is limited to gemcitabine plus cisplatin; however, this treatment is palliative in nature. Therefore, there is still a need to explore new effective therapeutic targets to intervene against CCA. METHODS: We analyzed the expression of EZH2 and the prognosis of patients in CCA...
December 2023: Clinical and Translational Medicine
https://read.qxmd.com/read/38037081/adipose-derived-exosomal-mir-421-targets-cbx7-and-promotes-metastatic-potential-in-ovarian-cancer-cells
#12
JOURNAL ARTICLE
Yi Zhang, Roslyn Tedja, Michael Millman, Terrence Wong, Alexandra Fox, Hussein Chehade, Meyer Gershater, Nicholas Adzibolosu, Radhika Gogoi, Matthew Anderson, Thomas Rutherford, Zhenggang Zhang, Michael Chopp, Gil Mor, Ayesha B Alvero
BACKGROUND: Chromobox protein homolog 7 (CBX7), a member of the Polycomb repressor complex, is a potent epigenetic regulator and gene silencer. Our group has previously reported that CBX7 functions as a tumor suppressor in ovarian cancer cells and its loss accelerated formation of carcinomatosis and drove tumor progression in an ovarian cancer mouse model. The goal of this study is to identify specific signaling pathways in the ovarian tumor microenvironment that down-regulate CBX7. Given that adipocytes are an integral component of the peritoneal cavity and the ovarian tumor microenvironment, we hypothesize that the adipose microenvironment is an important regulator of CBX7 expression...
November 30, 2023: Journal of Ovarian Research
https://read.qxmd.com/read/37986971/adipose-derived-exosomal-mir-421-targets-cbx7-and-promotes-metastatic-potential-in-ovarian-cancer-cells
#13
Yi Zhang, Roslyn Tedja, Michael Millman, Terrence Wong, Alexandra Fox, Hussein Chehade, Meyer Gershater, Nicholas Adzibolosu, Radhika Gogoi, Matthew Anderson, Thomas Rutherford, Zhenggang Zhang, Michael Chopp, Gil Mor, Ayesha B Alvero
BACKGROUND: Chromobox protein homolog 7 (CBX7), a member of the Polycomb repressor complex, is a potent epigenetic regulator and gene silencer. Our group has previously reported that CBX7 functions as a tumor suppressor in ovarian cancer cells and its loss accelerated formation of carcinomatosis and drove tumor progression in an ovarian cancer mouse model. The goal of this study is to identify specific signaling pathways in the ovarian tumor microenvironment that down-regulate CBX7. Given that adipocytes are an integral component of the peritoneal cavity and the ovarian tumor microenvironment, we hypothesize that the adipose microenvironment is an important regulator of CBX7 expression...
November 10, 2023: bioRxiv
https://read.qxmd.com/read/37981459/polycomb-repressor-complex-its-function-in-human-cancer-and%C3%A2-therapeutic-target-strategy
#14
REVIEW
Jingrong Liu, Hongjie Fan, Xinmiao Liang, Yang Chen
The Polycomb Repressor Complex (PRC) plays a pivotal role in gene regulation during development and disease, with dysregulation contributing significantly to various human cancers. The intricate interplay between PRC and cellular signaling pathways sheds light on cancer complexity. PRC presents promising therapeutic opportunities, with inhibitors undergoing rigorous evaluation in preclinical and clinical studies. In this review, we emphasize the critical role of PRC complex in gene regulation, particularly PcG proteins mediated chromatin compaction through phase separation...
November 17, 2023: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/37909018/exploring-the-therapeutic-potential-of-targeting-polycomb-repressive-complex-2-in-lung-cancer
#15
REVIEW
Min Gao, Yongwen Li, Peijun Cao, Hongyu Liu, Jun Chen, Shirong Kang
The pathogenesis of lung cancer (LC) is a multifaceted process that is influenced by a variety of factors. Alongside genetic mutations and environmental influences, there is increasing evidence that epigenetic mechanisms play a significant role in the development and progression of LC. The Polycomb repressive complex 2 (PRC2), composed of EZH1/2, SUZ12, and EED, is an epigenetic silencer that controls the expression of target genes and is crucial for cell identity in multicellular organisms. Abnormal expression of PRC2 has been shown to contribute to the progression of LC through several pathways...
2023: Frontiers in Oncology
https://read.qxmd.com/read/37862922/epigenetic-regulation-of-enhancer-of-zeste-homolog-2-ezh2-yin-yang-1-yy1-axis-in-cancer
#16
REVIEW
Nikhil Chandnani, Ishika Gupta, Vidhi Thakkar, Koustav Sarkar
In accordance with the World Health Organization, cancer is the second leading cause of death in patients. In recent years, the number of cancer patients has been growing, and the occurrence of cancer in people is becoming more common, primarily due to lifestyle factors. Yin Yang 1 (YY1) is a transcription factor that is widespread throughout. It is a zinc finger protein, falling under the GLI-Kruppel class. YY1 is known to regulate transcriptional activation and repression of various genes associated with different cellular processes such as DNA repair, autophagy, cell survival and apoptosis, and cell division...
October 10, 2023: Pathology, Research and Practice
https://read.qxmd.com/read/37771660/acquisition-of-neural-fate-by-combination-of-bmp-blockade-and-chromatin-modification
#17
JOURNAL ARTICLE
Agnes Lee Chen Ong, Toshiya Kokaji, Arisa Kishi, Yoshihiro Takihara, Takuma Shinozuka, Ren Shimamoto, Ayako Isotani, Manabu Shirai, Noriaki Sasai
Neural induction is a process where naive cells are converted into committed cells with neural characteristics, and it occurs at the earliest step during embryogenesis. Although the signaling molecules and chromatin remodeling for neural induction have been identified, the mutual relationships between these molecules are yet to be fully understood. By taking advantage of the neural differentiation system of mouse embryonic stem (ES) cells, we discovered that the BMP signal regulates the expression of several polycomb repressor complex (PRC) component genes...
October 20, 2023: IScience
https://read.qxmd.com/read/37734835/distinct-accessory-roles-of-arabidopsis-vel-proteins-in-polycomb-silencing
#18
JOURNAL ARTICLE
Elsa Franco-Echevarría, Mathias Nielsen, Anna Schulten, Jitender Cheema, Tomos E Morgan, Mariann Bienz, Caroline Dean
Polycomb repressive complex 2 (PRC2) mediates epigenetic silencing of target genes in animals and plants. In Arabidopsis , PRC2 is required for the cold-induced epigenetic silencing of the FLC floral repressor locus to align flowering with spring. During this process, PRC2 relies on VEL accessory factors, including the constitutively expressed VRN5 and the cold-induced VIN3. The VEL proteins are physically associated with PRC2, but their individual functions remain unclear. Here, we show an intimate association between recombinant VRN5 and multiple components within a reconstituted PRC2, dependent on a compact conformation of VRN5 central domains...
September 21, 2023: Genes & Development
https://read.qxmd.com/read/37729434/tp63-fusions-drive-multicomplex-enhancer-rewiring-lymphomagenesis-and-ezh2-dependence
#19
JOURNAL ARTICLE
Gongwei Wu, Noriaki Yoshida, Jihe Liu, Xiaoyang Zhang, Yuan Xiong, Tayla B Heavican-Foral, Elisa Mandato, Huiyun Liu, Geoffrey M Nelson, Lu Yang, Renee Chen, Katherine A Donovan, Marcus K Jones, Mikhail Roshal, Yanming Zhang, Ran Xu, Ajit J Nirmal, Salvia Jain, Catharine Leahy, Kristen L Jones, Kristen E Stevenson, Natasha Galasso, Nivetha Ganesan, Tiffany Chang, Wen-Chao Wu, Abner Louissaint, Lydie Debaize, Hojong Yoon, Paola Dal Cin, Wing C Chan, Shannan J Ho Sui, Samuel Y Ng, Andrew L Feldman, Steven M Horwitz, Karen Adelman, Eric S Fischer, Chun-Wei Chen, David M Weinstock, Myles Brown
Gene fusions involving tumor protein p63 gene (TP63) occur in multiple T and B cell lymphomas and portend a dismal prognosis for patients. The function and mechanisms of TP63 fusions remain unclear, and there is no target therapy for patients with lymphoma harboring TP63 fusions. Here, we show that TP63 fusions act as bona fide oncogenes and are essential for fusion-positive lymphomas. Transgenic mice expressing TBL1XR1::TP63, the most common TP63 fusion, develop diverse lymphomas that recapitulate multiple human T and B cell lymphomas...
September 20, 2023: Science Translational Medicine
https://read.qxmd.com/read/37708707/attenuated-salmonella-delivered-pd-1-sirna-enhances-the-antitumor-effects-of-ezh2-inhibitors-in-colorectal-cancer
#20
JOURNAL ARTICLE
Mengmeng Lv, Sheng Guo, Xinyu Zhang, Yan Zou, Qiang Chen, Chongyi Zang, Shuo Huang, Yuhan Hu, Yanling Wang, Qianqing Wang, Jiateng Zhong
Immunotherapy has made significant progress in the treatment of malignant tumors. However, strategies to combine immunotherapy with anticancer drugs have attracted great attention due to the low response rate and unique toxicity profile of immunotherapies and the subsequent development of acquired resistance in some initial responders. EZH2, a histone methyl transferase subunit of a Polycomb repressor complex,is highly expressed in a variety of tumors, and targeting EZH2 has become a new strategy for tumor therapy and drug combination...
September 12, 2023: International Immunopharmacology
keyword
keyword
110243
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.